vs
Beam Therapeutics Inc.（BEAM）与PATHWARD FINANCIAL, INC.（CASH）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是Beam Therapeutics Inc.的2.4倍（$276.3M vs $114.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 26.4%，领先187.7%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
BEAM vs CASH — 直观对比
营收规模更大
CASH
是对方的2.4倍
$114.1M
净利率更高
BEAM
高出187.7%
26.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $276.3M |
| 净利润 | $244.3M | $72.9M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | — |
| 净利率 | 214.1% | 26.4% |
| 营收同比 | 279.5% | — |
| 净利润同比 | 370.4% | — |
| 每股收益（稀释后） | $2.53 | $3.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMCASH
| Q1 26 | — | $276.3M | ||
| Q4 25 | $114.1M | $173.1M | ||
| Q3 25 | — | $186.7M | ||
| Q2 25 | — | $195.8M | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $182.6M | ||
| Q3 24 | — | $179.5M | ||
| Q2 24 | — | $188.6M |
净利润BEAMCASH
| Q1 26 | — | $72.9M | ||
| Q4 25 | $244.3M | $35.2M | ||
| Q3 25 | — | $38.8M | ||
| Q2 25 | — | $42.1M | ||
| Q1 25 | — | $75.0M | ||
| Q4 24 | — | $30.0M | ||
| Q3 24 | — | $33.5M | ||
| Q2 24 | — | $44.9M |
营业利润率BEAMCASH
| Q1 26 | — | — | ||
| Q4 25 | -15.3% | 24.6% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 24.1% | ||
| Q1 25 | — | 33.2% | ||
| Q4 24 | — | 19.8% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | — | 27.1% |
净利率BEAMCASH
| Q1 26 | — | 26.4% | ||
| Q4 25 | 214.1% | 20.3% | ||
| Q3 25 | — | 20.8% | ||
| Q2 25 | — | 21.5% | ||
| Q1 25 | — | 27.3% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | 18.7% | ||
| Q2 24 | — | 23.8% |
每股收益（稀释后）BEAMCASH
| Q1 26 | — | $3.35 | ||
| Q4 25 | $2.53 | $1.57 | ||
| Q3 25 | — | $1.69 | ||
| Q2 25 | — | $1.81 | ||
| Q1 25 | — | $3.14 | ||
| Q4 24 | — | $1.23 | ||
| Q3 24 | — | $1.34 | ||
| Q2 24 | — | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $157.6M |
| 总债务越低越好 | — | $59.5M |
| 股东权益账面价值 | $1.2B | $850.7M |
| 总资产 | $1.5B | $7.1B |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资BEAMCASH
| Q1 26 | — | $157.6M | ||
| Q4 25 | $1.2B | $331.2M | ||
| Q3 25 | — | $120.6M | ||
| Q2 25 | — | $258.3M | ||
| Q1 25 | — | $254.2M | ||
| Q4 24 | — | $597.4M | ||
| Q3 24 | — | $158.3M | ||
| Q2 24 | — | $298.9M |
总债务BEAMCASH
| Q1 26 | — | $59.5M | ||
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $33.5M | ||
| Q2 25 | — | $33.4M | ||
| Q1 25 | — | $33.4M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $33.3M |
股东权益BEAMCASH
| Q1 26 | — | $850.7M | ||
| Q4 25 | $1.2B | $854.5M | ||
| Q3 25 | — | $858.0M | ||
| Q2 25 | — | $819.0M | ||
| Q1 25 | — | $814.7M | ||
| Q4 24 | — | $758.3M | ||
| Q3 24 | — | $822.5M | ||
| Q2 24 | — | $748.4M |
总资产BEAMCASH
| Q1 26 | — | $7.1B | ||
| Q4 25 | $1.5B | $7.6B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | — | $7.2B | ||
| Q1 25 | — | $7.0B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.5B | ||
| Q2 24 | — | $7.5B |
负债/权益比BEAMCASH
| Q1 26 | — | 0.07× | ||
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMCASH
| Q1 26 | — | — | ||
| Q4 25 | $-83.3M | $108.3M | ||
| Q3 25 | — | $303.7M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $188.3M | ||
| Q4 24 | — | $-71.7M | ||
| Q3 24 | — | $143.1M | ||
| Q2 24 | — | $113.2M |
自由现金流BEAMCASH
| Q1 26 | — | — | ||
| Q4 25 | $-87.0M | $104.1M | ||
| Q3 25 | — | $300.3M | ||
| Q2 25 | — | $27.7M | ||
| Q1 25 | — | $184.7M | ||
| Q4 24 | — | $-73.8M | ||
| Q3 24 | — | $138.8M | ||
| Q2 24 | — | $111.0M |
自由现金流率BEAMCASH
| Q1 26 | — | — | ||
| Q4 25 | -76.3% | 60.1% | ||
| Q3 25 | — | 160.9% | ||
| Q2 25 | — | 14.1% | ||
| Q1 25 | — | 67.2% | ||
| Q4 24 | — | -40.4% | ||
| Q3 24 | — | 77.3% | ||
| Q2 24 | — | 58.8% |
资本支出强度BEAMCASH
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 2.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 1.2% |
现金转化率BEAMCASH
| Q1 26 | — | — | ||
| Q4 25 | -0.34× | 3.08× | ||
| Q3 25 | — | 7.83× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 2.51× | ||
| Q4 24 | — | -2.39× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 2.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
